Adam Buckley, VBI’s Vice President of Operations, will be attending the BIO-Europe Conference being held this week in Frankfurt, Germany. Mr. Buckley is representing VBI in BIO-Europe’s Partnering Program. To...
Read More
With funding from a five-year, $2.3M NIH grant, researchers at the University of Arizona College of Medicine are studying how cytomegalovirus (CMV) may impact immune system function as we age....
Read More
Congenital CMV infection often goes undetected because the majority of affected infants do not present symptoms at birth; routine screening of newborns could allow infected infants to receive better care....
Read More
While many potential risk factors for brain cancer have been identified, including smoking and alcohol consumption, various pathogenic infections, including cytomegalovirus ("CMV"), may also constitute an under-appreciated but significant risk....
Read More
Dr. David E. Anderson, VBI’s Senior Vice President of Research, will present this week at the Biotech in Europe Investor Forum. The two-day event will begin tomorrow, September 30th, in...
Read More
Last year, Utah became the first state to pass legislation designed to improve CMV awareness and screening for those most at risk. On June 14th, 2013, Governor Gary Herbert signed...
Read More
VBI is developing a prophylactic CMV vaccine; VBI's Senior Vice President of Research will discuss the vaccine candidate's design, preclinical data, and manufacturing process. The Presentation will begin at 10:45AM...
Read More
Each year, a significant portion of vaccines lose their potency, become ineffective, or can become hazardous due to problems in transportation and storage. These failures add to the overall cost...
Read More
Rapid, potent, and durable immunity demonstrated with vaccine candidate (VBI-1501A). Pilot scale (10L) production of VBI-1501A expected to meet Phase I trial release criteria. VBI presented new data last week...
Read More
The presentation, A Prophylactic Human Cytomegalovirus (HCMV) Vaccine Designed to Prevent Congenital Infection Using Enveloped Virus-Like-Particles (eVLPs), was delivered by Dr. David E. Anderson, VBI’s Senior Vice President of Research,...
Read More